Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective in treating tumors harboring alterations in the mTOR pathway. Mechanisms of resistance to everolimus remain undefined. Resistance developed in a patient with metastatic anaplastic thyroid carcinoma after an extraordin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:N Engl J Med
Autori principali: Wagle, Nikhil, Grabiner, Brian C., Van Allen, Eliezer M., Amin-Mansour, Ali, Taylor-Weiner, Amaro, Rosenberg, Mara, Gray, Nathanael, Barletta, Justine A., Guo, Yanan, Swanson, Scott J., Ruan, Daniel T., Hanna, Glenn J., Haddad, Robert I., Getz, Gad, Kwiatkowski, David J., Carter, Scott L., Sabatini, David M., Jänne, Pasi A., Garraway, Levi A., Lorch, Jochen H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4564868/
https://ncbi.nlm.nih.gov/pubmed/25295501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1403352
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi